Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

August 20, 2019

Study Completion Date

August 20, 2019

Conditions
Diabetes After Total Pancreatectomy
Interventions
DRUG

Sitagliptin 100mg

"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."

DRUG

Empagliflozin 25 MG

2 tablets of empagliflozin 25 mg.

OTHER

Placebo tablet

"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."

Trial Locations (1)

2900

Center for Clinical Metabolic Research, Hellerup

All Listed Sponsors
lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT04061473 - Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion | Biotech Hunter | Biotech Hunter